|
|
|
| Clinical study of diabetic nephropathy in early stage treated with atorvastatin and irbesartan |
| ZHOU Xiyu1,BAI Yongmei1,XU Xiaogang1,YANG Jianqiang1,LIU Zude2 |
1.Department of Nephrology,Shaanxi Provincial Corps Hospital, Chinese People’s Armed Polices Forces, Xi’an 710054,China;
2. Department of Pharmacy, General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China |
|
|
|
|
Abstract Objective To study the clinical effect of combined use of atorvastatin combined with irbesartan in the treatment of early diabetic nephropathy. Methods Fighty patients with early diabetic nephropathy who met the diagnostic criteria were randomly divided into three groups:control group(n=25),treatment group A (n=25), treatment group B (n=25). All patients received daily diabetes routine treatment, treatment group A received irbesartan 150 mg qd, treatment group B received atorvastatin 20 mg qd, treatment group C received both irbesartan (150 mg qd) and atorvastatin(20 mg qd). The study courses were three months for all groups. TC, TG, HDL-C, FPG, 2 hPG, HbA1c, serum creatinine (Scr), urinary albumin (U-mAlb), urinary β2 microglobulin (β2-MG) were tested before and after the treatments. Results The FPG, 2 hPG, HbA1c were significantly lower after the treatment in all groups(P<0.05), and there was no statistical difference between groups. U-mAlb, U-β2MG, Scr in groups A and B were significantly lower than those before treatment,and there were statistically significant differences between before and after treatment (P<0.05). TC, TG, HDL-C in the contral group were not significantlg different before and after treatment (P>0.05). TC, TG in groups A and B were significantly lower than those before treatment,and HDL-C increased, with significant difference (P<0.05) . Conclusions Atorvastatin combined with irbesartan can effectively mitigate or reverse the early diabetic nephropathy patients with glomerular and renal tubular injury; the mechanism may be related to its combination of intensive lipid-lowering and strengthening the inhibition of RASS system.
|
|
Received: 10 June 2013
|
|
|
|
|
|
| [1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(7): 626-628. |
|
|
|
|
2014, Vol. 25 
